STRATEC Biomedical Reports Increased Profitability Despite Sales Dip

STRATEC Biomedical reported a mixed financial performance for the first nine months of 2026, with a notable increase in profitability offsetting a decline in sales. The company’s adjusted EBIT margin rose to 8.3% – up from 7.3% in the same period last year – while consolidated sales fell by 5.0% on a constant currency basis to €164.9 million.

The improved margin, reaching 11.3% in the third quarter alone, signals increased efficiency and cost control despite lower revenue. This positive trend was further underscored by a substantial increase in operating cash flow, which grew to €39.4 million, a dramatic turnaround from the €-1.4 million loss reported in the first nine months of 2025. This improvement is attributed to focused working capital management and the benefit of a strong year-end performance in 2025.

The sales decline was primarily driven by lower performance in the Service Parts and Consumables businesses, attributed to customers optimizing logistics following ownership changes. While management expects this to be a temporary effect, the timing of a recovery remains uncertain. Notably, the company is in the process of divesting its Diatron Group, signing an agreement with a consortium of Indian investors in the fourth quarter, which is expected to further boost profitability and allow STRATEC to focus on its core business.

Looking ahead, STRATEC anticipates stable to slightly higher sales volumes on a constant-currency basis for the full year 2026, with an adjusted EBIT margin projected between 13.0% and 15.0%. The company is also increasing investment in property, plant, and equipment, and intangible assets, expected to be 5.0% to 7.0% of sales this year. The strengthened cash flow and strategic divestiture position STRATEC to capitalize on opportunities in high-end analyzer systems and lifecycle management, navigating a consolidating sector with evolving regulatory demands.